Literature DB >> 11997288

Adenylyl cyclase increases survival in cardiomyopathy.

David M Roth1, Hamed Bayat, Jeffrey D Drumm, Mei Hua Gao, James S Swaney, Aziz Ander, H Kirk Hammond.   

Abstract

BACKGROUND: To test the hypothesis that increased cardiac adenylyl cyclase type VI (AC(VI)) content, which results in increased cAMP generation, would increase survival in cardiomyopathy, we crossbred mice with Gq-associated cardiomyopathy and those with cardiac-directed expression of AC(VI). We also assessed myocardial hypertrophy after prolonged cardiac expression of Gq versus coexpression of Gq and AC(VI). METHODS AND
RESULTS: Three experimental groups, Gq/AC (double positive), Gq, and control (double negative), were studied. Survival was increased by cardiac-directed expression of AC(VI) (P<0.0001), and Gq/AC mice had survival rates indistinguishable from control mice. Myocardial hypertrophy developed in older Gq mice but was abrogated by cardiac expression of AC(VI), as documented by the ratio of ventricular weight to tibial length (Gq, 11.93+/-0.99 mg/mm, n=11; Gq/AC, 8.00+/-0.73 mg/mm, n=9; P<0.01) and by left ventricular cardiac myocyte size (Gq, 2800+/-254 microm2, n=4; Gq/AC, 1721+/-166 microm2, n=5; P<0.01). Hearts of Gq mice were dilated, and function was impaired. Concurrent expression of AC reduced end-diastolic diameter (Gq, 4.20+/-0.15 mm, n=12; Gq/AC, 3.68+/-0.12 mm, n=7; P<0.05) and increased fractional shortening (Gq, 32+/-1%, n=12; Gq/AC, 41+/-2%, n=7; P<0.001). Cardiac myocytes from Gq/AC mice showed increased forskolin-stimulated cAMP production (Gq, 3.8+/-1.3 fmol/cell, n=5; Gq/AC, 10.7+/-2.6 fmol/cell, n=6; P<0.02), documenting increased AC function.
CONCLUSIONS: Cardiac-directed expression of AC(VI) restores myocyte AC function, improves heart function, increases cAMP generation, abrogates myocardial hypertrophy, and increases survival in Gq cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11997288     DOI: 10.1161/01.cir.0000014968.54967.d3

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  51 in total

1.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

2.  Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.

Authors:  H Kirk Hammond; William F Penny; Jay H Traverse; Timothy D Henry; Matthew W Watkins; Clyde W Yancy; Ranya N Sweis; Eric D Adler; Amit N Patel; David R Murray; Robert S Ross; Valmik Bhargava; Alan Maisel; Denise D Barnard; N Chin Lai; Nancy D Dalton; Martin L Lee; Sanjiv M Narayan; Daniel G Blanchard; Mei Hua Gao
Journal:  JAMA Cardiol       Date:  2016-05-01       Impact factor: 14.676

Review 3.  Prospects for gene transfer for clinical heart failure.

Authors:  T Tang; M H Gao; H Kirk Hammond
Journal:  Gene Ther       Date:  2012-04-26       Impact factor: 5.250

4.  Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice.

Authors:  Tong Tang; N Chin Lai; H Kirk Hammond; David M Roth; Yuan Yang; Tracy Guo; Mei Hua Gao
Journal:  J Am Coll Cardiol       Date:  2010-04-06       Impact factor: 24.094

5.  Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes.

Authors:  Mei Hua Gao; Tong Tang; Tracy Guo; Atsushi Miyanohara; Toshitaka Yajima; Kersi Pestonjamasp; James R Feramisco; H Kirk Hammond
Journal:  J Biol Chem       Date:  2008-10-05       Impact factor: 5.157

Review 6.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

Review 7.  Gene therapy targets in heart failure: the path to translation.

Authors:  P W J Raake; H Tscheschner; J Reinkober; J Ritterhoff; H A Katus; W J Koch; P Most
Journal:  Clin Pharmacol Ther       Date:  2011-08-24       Impact factor: 6.875

8.  Cardiac adenylyl cyclase overexpression precipitates and aggravates age-related myocardial dysfunction.

Authors:  Nathalie Mougenot; Delphine Mika; Gabor Czibik; Elizabeth Marcos; Shariq Abid; Amal Houssaini; Benjamin Vallin; Aziz Guellich; Hind Mehel; Daigo Sawaki; Grégoire Vandecasteele; Rodolphe Fischmeister; Roger J Hajjar; Jean-Luc Dubois-Randé; Isabelle Limon; Serge Adnot; Geneviève Derumeaux; Larissa Lipskaia
Journal:  Cardiovasc Res       Date:  2019-10-01       Impact factor: 10.787

9.  Adenylyl cyclase 6 deletion increases mortality during sustained β-adrenergic receptor stimulation.

Authors:  Tong Tang; N Chin Lai; Adam T Wright; Mei Hua Gao; Paul Lee; Tracy Guo; Ruoying Tang; Andrew D McCulloch; H Kirk Hammond
Journal:  J Mol Cell Cardiol       Date:  2013-04-12       Impact factor: 5.000

10.  Effect of overexpressed adenylyl cyclase VI on beta 1- and beta 2-adrenoceptor responses in adult rat ventricular myocytes.

Authors:  Joalice C C Stark; Stephen F Haydock; Roger Foo; Morris J Brown; Sian E Harding
Journal:  Br J Pharmacol       Date:  2004-09-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.